Skip to main content
SpringerLink
Log in

Association of POLK Polymorphisms with Platinum-Based Chemotherapy Response and Severe Toxicity in Non-small Cell Lung Cancer Patients

  • Original Paper
  • Published:
Cell Biochemistry and Biophysics Aims and scope Submit manuscript

Abstract

Lung cancer is the leading cause of tumor-derived death. Although target therapy is proven very efficient, traditionally platinum-based chemotherapies are still primary treatment for most patients. Platinum can suppress the tumor growth and impair normal cells together. The primary aim of the present study was to study the potential role of translesion synthesis (TLS) that might play in platinum-chemotherapy tolerance and side-effect. In present study, a total of 663 patients who were newly histologically diagnosed with advanced NSCLC (aNSCLC) were enrolled. Treatment response was classified into four categories: complete response, partial response, stable disease, and progressive disease. Incidence of gastrointestinal and hematological toxicities was assessed twice a week during the whole first-line treatment. Eleven SNPs of POLK were genotyped. The associations between SNPs and treatment response or toxicity were analyzed with logistic regression model. Cox regression was used for survival analysis between SNPs and progression-free survival or overall survival. We identified that rs3213801 and rs5744533 showed complete linkage in the present study, and they were significantly associated with treatment response (adjusted P = 0.044), together with rs5744655 (adjusted P = 0.039). rs1018119 was correlated with gastrointestinal toxicity in smokers specially (adjusted P = 0.041). Besides, rs3756558 was associated with hematological toxicity and overall toxicity in smokers and combined cohort with additive model. We also identified the significant association between two SNPs, rs10077427 and rs5744545, and PFS. The polymorphism of POLK, an important gene in TLS, participates in platinum-chemotherapy tolerance and side-effect.

This is a preview of subscription content, log in via an institution to check access.

Access this article

Log in via an institution

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

Fig. 1

Similar content being viewed by others

References

  1. Siegel, R., Naishadham, D., & Jemal, A. (2013). Cancer statistics, 2013. CA: A Cancer Journal for Clinicians, 63(1), 11–30.

    Google Scholar 

  2. Mountain, C. F. (1997). Revisions in the international system for staging lung cancer. Chest, 111(6), 1710–1717.

    Article  PubMed  CAS  Google Scholar 

  3. Jemal, A., Bray, F., Center, M. M., Ferlay, J., Ward, E., & Forman, D. (2011). Global cancer statistics. CA: A Cancer Journal for Clinicians, 61(2), 69–90.

    Google Scholar 

  4. Pao, W., et al. (2004). EGF receptor gene mutations are common in lung cancers from “never smokers” and are associated with sensitivity of tumors to gefitinib and erlotinib. Proceedings of the National Academy of Sciences of the United States of America, 101(36), 13306–13311.

    Article  PubMed  CAS  PubMed Central  Google Scholar 

  5. Lynch, T. J., et al. (2004). Activating mutations in the epidermal growth factor receptor underlying responsiveness of non-small-cell lung cancer to gefitinib. New England Journal of Medicine, 350(21), 2129–2139.

    Article  PubMed  CAS  Google Scholar 

  6. Jordan, M. A., & Wilson, L. (2004). Microtubules as a target for anticancer drugs. Nature Reviews Cancer, 4(4), 253–265.

    Article  PubMed  CAS  Google Scholar 

  7. Quoix, E., et al. (2011). Carboplatin and weekly paclitaxel doublet chemotherapy compared with monotherapy in elderly patients with advanced non-small-cell lung cancer: IFCT-0501 randomised, phase 3 trial. Lancet, 378(9796), 1079–1088.

    Article  PubMed  CAS  Google Scholar 

  8. Lara, P. N, Jr, et al. (2011). Randomized phase III placebo-controlled trial of carboplatin and paclitaxel with or without the vascular disrupting agent vadimezan (ASA404) in advanced non-small-cell lung cancer. Journal of Clinical Oncology, 29(22), 2965–2971.

    Article  PubMed  CAS  Google Scholar 

  9. Rabik, C. A., & Dolan, M. E. (2007). Molecular mechanisms of resistance and toxicity associated with platinating agents. Cancer Treatment Reviews, 33(1), 9–23.

    Article  PubMed  CAS  PubMed Central  Google Scholar 

  10. Martin, L. P., Hamilton, T. C., & Schilder, R. J. (2008). Platinum resistance: The role of DNA repair pathways. Clinical Cancer Research, 14(5), 1291–1295.

    Article  PubMed  CAS  Google Scholar 

  11. Olaussen, K. A., et al. (2006). DNA repair by ERCC1 in non-small-cell lung cancer and cisplatin-based adjuvant chemotherapy. New England Journal of Medicine, 355(10), 983–991.

    Article  PubMed  CAS  Google Scholar 

  12. Gurubhagavatula, S., et al. (2004). XPD and XRCC1 genetic polymorphisms are prognostic factors in advanced non-small-cell lung cancer patients treated with platinum chemotherapy. Journal of Clinical Oncology, 22(13), 2594–2601.

    Article  PubMed  CAS  Google Scholar 

  13. Waters, L. S., et al. (2009). Eukaryotic translesion polymerases and their roles and regulation in DNA damage tolerance. Microbiology and Molecular Biology Reviews, 73(1), 134–154.

    Article  PubMed  CAS  PubMed Central  Google Scholar 

  14. Wojtaszek, J., et al. (2012). Multifaceted recognition of vertebrate Rev1 by translesion polymerases zeta and kappa. Journal of Biological Chemistry, 287(31), 26400–26408.

    Article  PubMed  CAS  PubMed Central  Google Scholar 

  15. Ceppi, P., et al. (2009). Polymerase eta mRNA expression predicts survival of non-small cell lung cancer patients treated with platinum-based chemotherapy. Clinical Cancer Research, 15(3), 1039–1045.

    Article  PubMed  CAS  Google Scholar 

  16. Nojima, K., et al. (2005). Multiple repair pathways mediate tolerance to chemotherapeutic cross-linking agents in vertebrate cells. Cancer Research, 65(24), 11704–11711.

    Article  PubMed  CAS  Google Scholar 

  17. Chen, Y. W., et al. (2006). A novel role of DNA polymerase eta in modulating cellular sensitivity to chemotherapeutic agents. Molecular Cancer Research, 4(4), 257–265.

    Article  PubMed  CAS  Google Scholar 

  18. Doles, J., et al. (2010). Suppression of Rev3, the catalytic subunit of Pol zeta, sensitizes drug-resistant lung tumors to chemotherapy. Proceedings of the National Academy of Sciences of the United States of America, 107(48), 20786–20791.

    Article  PubMed  CAS  PubMed Central  Google Scholar 

  19. Zhou, W., et al. (2013). Expression of DNA translesion synthesis polymerase eta in head and neck squamous cell cancer predicts resistance to gemcitabine and cisplatin-based chemotherapy. PLoS One, 8(12), e83978.

    Article  PubMed  PubMed Central  Google Scholar 

  20. [20]. Li, Z., et al. (2009). A partition-ligation-combination-subdivision EM algorithm for haplotype inference with multiallelic markers: update of the SHEsis (http://analysis.bio-x.cn). Cell Research, 19(4), 519–523.

  21. Shi, Y. Y., & He, L. (2005). SHEsis, a powerful software platform for analyses of linkage disequilibrium, haplotype construction, and genetic association at polymorphism loci. Cell Research, 15(2), 97–98.

    Article  PubMed  CAS  Google Scholar 

  22. Betous, R., et al. (2013). DNA polymerase kappa-dependent DNA synthesis at stalled replication forks is important for CHK1 activation. EMBO Journal, 32(15), 2172–2185.

    Article  PubMed  CAS  PubMed Central  Google Scholar 

  23. Bavoux, C., et al. (2005). Up-regulation of the error-prone DNA polymerase kappa promotes pleiotropic genetic alterations and tumorigenesis. Cancer Research, 65(1), 325–330.

    PubMed  CAS  Google Scholar 

  24. O-Wang, J., et al. (2001). DNA polymerase kappa, implicated in spontaneous and DNA damage-induced mutagenesis, is overexpressed in lung cancer. Cancer Research, 61(14), 5366–5369.

    PubMed  CAS  Google Scholar 

  25. Wang, Y., et al. (2004). Elevated expression of DNA polymerase kappa in human lung cancer is associated with p53 inactivation: Negative regulation of POLK promoter activity by p53. International Journal of Oncology, 25(1), 161–165.

    PubMed  Google Scholar 

  26. Bergoglio, V., et al. (2002). Localisation of human DNA polymerase kappa to replication foci. Journal of Cell Science, 115(Pt 23), 4413–4418.

    Article  PubMed  CAS  Google Scholar 

  27. Haracska, L., et al. (2002). Stimulation of DNA synthesis activity of human DNA polymerase kappa by PCNA. Molecular and Cellular Biology, 22(3), 784–791.

    Article  PubMed  CAS  PubMed Central  Google Scholar 

  28. Zhang, Y., et al. (2000). Error-free and error-prone lesion bypass by human DNA polymerase kappa in vitro. Nucleic Acids Research, 28(21), 4138–4146.

    Article  PubMed  CAS  PubMed Central  Google Scholar 

  29. Bavoux, C., Hoffmann, J. S., & Cazaux, C. (2005). Adaptation to DNA damage and stimulation of genetic instability: the double-edged sword mammalian DNA polymerase kappa. Biochimie, 87(7), 637–646.

    Article  PubMed  CAS  Google Scholar 

  30. Xu, H. L., et al. (2013). Effects of polymorphisms in translesion DNA synthesis genes on lung cancer risk and prognosis in Chinese men. Cancer Epidemiology, 37(6), 917–922.

    Article  PubMed  Google Scholar 

  31. Michiels, S., et al. (2007). Polymorphism discovery in 62 DNA repair genes and haplotype associations with risks for lung and head and neck cancers. Carcinogenesis, 28(8), 1731–1739.

    Article  PubMed  CAS  Google Scholar 

  32. Han, J., et al. (2009). Genetic variation in DNA repair pathway genes and premenopausal breast cancer risk. Breast Cancer Research and Treatment, 115(3), 613–622.

    Article  PubMed  CAS  PubMed Central  Google Scholar 

Download references

Acknowledgments

This work was supported by the China National Key Basic Research Program Grants 81172104 (to BH HAN).

Conflict of interest

All the authors declare no conflict of interest.

Author information

Authors and Affiliations

  1. Department of Pulmonary Medicine, Shanghai Chest Hospital Affiliated to Jiaotong University, Shanghai, China

    Minhua Shao, Bo Jin, Yanjie Niu & Baohui Han

  2. Institutes of Biomedical Sciences, Fudan University, Shanghai, China

    Junyi Ye

  3. State Key Laboratory of Genetic Engineering and MOE Key Laboratory of Contemporary Anthropology, School of Life Sciences and Institutes for Biomedical Sciences, Fudan University, Shanghai, China

    Daru Lu

Authors
  1. Minhua Shao
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. Bo Jin
    View author publications

    You can also search for this author in PubMed Google Scholar

  3. Yanjie Niu
    View author publications

    You can also search for this author in PubMed Google Scholar

  4. Junyi Ye
    View author publications

    You can also search for this author in PubMed Google Scholar

  5. Daru Lu
    View author publications

    You can also search for this author in PubMed Google Scholar

  6. Baohui Han
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding author

Correspondence to Baohui Han.

Additional information

Minhua Shao and Bo Jin have contributed equally to this work.

Rights and permissions

Reprints and permissions

About this article

Check for updates. Verify currency and authenticity via CrossMark

Cite this article

Shao, M., Jin, B., Niu, Y. et al. Association of POLK Polymorphisms with Platinum-Based Chemotherapy Response and Severe Toxicity in Non-small Cell Lung Cancer Patients. Cell Biochem Biophys 70, 1227–1237 (2014). https://doi.org/10.1007/s12013-014-0046-x

Download citation

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1007/s12013-014-0046-x

Keywords

Search

Navigation